Loading
EB
Ensysce Biosciences, Inc. Stock: price and insider trades · United States
1 insider bought €382k of shares over the last 90 days, the latest by GOWER BOB G, filed 18 Aug 2026.
Ensysce Biosciences, Inc.: what insiders have been doing
Ensysce Biosciences, Inc., founded in 2003, is a Healthcare & Pharma company based in United States. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 2 filings came from 1 insider.
Only purchases show up on the open market, 2 purchases in all worth €382k, filed by 1 insider. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Gower Bob G filed the largest purchase, €211k, on 18 August 2026. Among those who bought: 1 senior executive.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 2 filings, this issuer sits below that mark. Over the whole record (from 2021), the tally stands at 6 purchases and no sales.
The last insider purchase was made public on 18 August 2026, 61 days ago.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Key facts
Headquarters: United States · Founded: 2003
Source: Wikidata (CC0).
Insider Decl.
10
Thresholds
n/a
Buy Volume
€979,509
6 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleBob G. Gower2 buys
Since the insiders bought
- +18.0%Entry US$0.39 · Close at T+30 US$0.46
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.52
Analyst consensus
1 analystsUS$8.25Target US$8.25(+1493%)US$8.25
Income statement
RevenueUS$4.4M
EBITDA-US$10.2M-233% margin
Net income-US$10.2M-280.5% margin
Valuation
PER (forward)-10.4x
Beta1.02
Balance sheet & cash
Market capUS$10.1M
Total debtUS$306.7k
Free Cash Flow-US$7.9M
Profitability & ownership
ROE-1295.1%
ROA-185.5%
% insiders4.7%
% institutions4.7%
Last declaration on 18 August 2026
Declarations10 total
508,614 shares@ US$0.48422.2% of flowCommon StockSEC:0001493152-26-038866:0
Canonical exit: 22 Jul 2026 (T+90)
400,000 shares@ US$0.49518.1% of flowCommon StockSEC:0001493152-26-038866:1
Canonical exit: 5 Nov 2026 (T+90)
90,287 shares@ US$0.48834.4% of flowCommon StockSEC:0001493152-23-006786:0
Canonical exit: 31 May 2023 (T+90)
109,300 shares@ US$0.48835.3% of flowCommon StockSEC:0001493152-23-006553:0
Canonical exit: 29 May 2023 (T+90)
357,143 shares@ US$1.4050.0% of flowCommon StockSEC:0001493152-23-003343:0
Canonical exit: 9 Mar 2023 (T+90)
70,000 shares@ US$0.4869100.0% of flowCommon StockSEC:0001493152-22-015294:0
Canonical exit: 23 Aug 2022 (T+90)
7,919,026 sharesCommon StockSEC:0001192482-21-000620:0
284,851 sharesCommon StockSEC:0001192482-21-000618:0
353,451 sharesCommon StockSEC:0001493152-21-016122:0
50,000 shares0Common StockSEC:0001493152-21-016123:0
10 of 10 declarations
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc. is a U.S.-listed biotechnology company traded on the NASDAQ market in the United States. It operates in a specialized, high-need area of healthcare: oral drug delivery technologies designed to improve severe pain treatment while reducing the risks of abuse, misuse, and overdose associated with prescription medicines. The company’s core differentiation rests on proprietary chemistry platforms, especially TAAP™ (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance), which are intended to control when and how a drug is activated and to add an overdose-protection layer to opioid-based therapies. ([ensysce.com](https://ensysce.com/about-us/?utm_source=openai))
Ensysce was built as a research-driven biotech organization led for many years by D. Lynn Kirkpatrick, PhD, who became President and CEO in January 2009 according to company archives. Over time, the company evolved from a broader chemistry and drug-delivery concept into a focused clinical-stage pain-safety platform. Its corporate history reflects the typical profile of an early-to-midstage biotech: heavy emphasis on intellectual property, preclinical and clinical execution, and financing rather than commercial revenue generation. ([ir.ensysce.com](https://ir.ensysce.com/news/press-releases/detail/33/ensysce-biosciences-inc-appoints-dr-d-lynn-kirkpatrick?utm_source=openai))
Read moreShow less
In terms of business lines, Ensysce is concentrated around a narrow pipeline and a small number of platform-enabled assets. Its lead candidate is PF614, an oxycodone prodrug designed for severe and/or chronic pain. A second key program is PF614-MPAR, which pairs PF614 with overdose-protection functionality. The company’s positioning is therefore not that of a broad painpharma franchise, but of a technology-led developer of safer oral opioid medicines. Competitive positioning depends on whether Ensysce can demonstrate meaningful clinical benefit, safety differentiation, and patent-protected durability against larger pharmaceutical groups and other abuse-deterrent technology developers. ([stockanalysis.com](https://stockanalysis.com/stocks/ensc/company/?utm_source=openai))
Geographically, Ensysce’s operations are primarily centered in the United States, with development, clinical, and regulatory activity largely U.S.-based. For investors in Europe, this means the equity should be viewed as a U.S. clinical biotech story rather than a diversified global healthcare company. The company highlights collaborations and external expertise to support execution, which is important given the complexity of pain therapeutics and the regulatory scrutiny around opioids. ([ensysce.com](https://ensysce.com/about-us/?utm_source=openai))
Recent company updates indicate continued pipeline advancement rather than commercialization. In 2026, Ensysce announced expanded patent protection for its MPAR overdose-protection technology, the CEO presented at a clinical pain symposium in Amsterdam, and the company secured IRB approval for the final phase of the PF614-MPAR-102 clinical study. It also reported full-year 2025 financial results in March 2026 and disclosed a second financing under a 2025 agreement to advance its pain programs. Taken together, these developments suggest an enterprise still in development mode, where valuation is primarily driven by clinical milestones, funding availability, and the strength of its intellectual-property moat. ([ensysce.com](https://ensysce.com/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
